Retrospective cost analysis of breast cancer patients treated in a Brazilian outpatient cancer center (OCC).

Teich, Nelson; Pepe, C.; Vieira, F. M.; Teich, V; Cintra, Mariângela Torreglosa Ruiz; Leibel, Fernando; Boukai, Alexandre; Helal, R. C.; Victorino, A. O.; Musacchio, J. G.

doi:10.1200/jco.2010.28.15_suppl.e11026

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our study align with the findings of previous studies [8,12,25,31], stating that the direct medical cost per patient increases with progressive disease stages. Moreover, the highest total direct medical expense was incurred in stage IV of BC.…”

Section: Discussionsupporting

confidence: 92%

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Alefan

Saadeh

Yaghan

2020

Breast Cancer Manag.

View full text Add to dashboard Cite

Aim: To analyze the direct medical costs of breast cancer (BC) patients in the north of Jordan. Patients: A cohort of BC patients treated during 2015 at King Abdullah University Hospital. Methods: A retrospective analysis of 119 patients, where all records including age, sex, treatment processes and costs were extracted from the patients’ profiles and examined. Results: The mean age of patients was 50.8 (±10.2) years. The total sample cost was Jordanian dinar 1,393,325 (US$1,963,560). The mean cost per patient from stage I to IV was Jordanian dinar 6696, 9183, 11,970 and 15,073, respectively. Medications were the most expensive resource used. Stage IV had the highest cost and largest number of patients. Conclusion: Direct medical costs associated with BC are considerable. Three-quarters of the cost were devoted to medications.

show abstract

Section: Discussionsupporting

confidence: 92%

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Alefan

Saadeh

Yaghan

2020

Breast Cancer Manag.

View full text Add to dashboard Cite

show abstract

“…[29] The results of this study also show that the direct treatment costs in the stages III and IV were significantly higher than the early stages; though their cost are much higher than the costs in Iran.…”

Section: Discussionmentioning

confidence: 58%

“…Assessment of direct costs of breast cancer has been done in some other countries,[293031] but it is not always possible to compare the results of these studies because of various methodology used to calculate the cost of treatment, different perspective and various socio-economic conditions. [323334] Nonetheless, all studies[3031] confirm that medication therapy was the most costly part of treatment in III and IV stages, which is also compatible with the results of our study.…”

Section: Discussionmentioning

confidence: 99%

The direct medical costs of colorectal cancer in Iran; analyzing the patient′s level data from a cancer specific hospital in Isfahan

Davari¹,

Maracy²,

Emami³

et al. 2012

Int J Prev Med

View full text Add to dashboard Cite

Background:The Immense cost of cancer treatment is one of the main challenges of health care systems all over the world including Iran. The aim of this study was to analyze the direct treatment costs of colorectal cancer patients in Isfahan, Iran.Methods:In this cross sectional study, the medical records of colorectal cancer (CRC) patients admitted to the Seyyed-al-Shohada Hospital “SSH” from 2005-2010 were reviewed. The profiles of 452 patients were examined. However based on inclusion, exclusion criteria a total number of 432 profiles were analyzed. All records including age, sex, treatment processes and treatment costs were extracted from the patients’ profiles and analyzed using Kruskal-Wallis test.Findings:The results showed that 56.1% of CRC patients were male. The mean age of patients suffering from CRC was 56 ± 13.4. More than Thirty-six percent of the patients were in stages 1-3 of CRC and more than half of them (64.4%) were in the 4th stage. The higher the stage of the cancer the higher the percentage of treatments used. 5-Fluorouracil and Leucovorin (5FU/LV) was the most common used chemical treatment protocol. The mean treatment cost for stage one was 10715 (±4927), for stage two 15920 (±3440), stage three 16452 (±2828) and for stage four was 16723 (±2555) US Dollars. The cost of drug treatment was the first cost driven between the medical services.Conclusion:CRC in Iranian population starts in younger age than people in western countries. This imposed considerable direct and indirect economic cost to the society. The direct medical cost of colorectal cancer in Iran is very higher than 38 million $. Screening programs could reduce the economic cost of CRC significantly.

show abstract

“…The results show differential costs due to the fact that each sector follows different treatment alternatives. The average annual cost per patient for the private sector was 15,426 US$ compared to 4,757 US$ for the public sector [ 7 , 8 ]. In Mexico, Knaul et al , conducted a study in Mexico in a social security institution with data from 2006, estimating the average cost per year per patient to be 6734 US$ [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Costs of breast cancer care in Mexico: analysis of two insurance coverage scenarios

González-Robledo

Wong²,

Ornelas³

et al. 2015

ecancer

View full text Add to dashboard Cite

BackgroundBreast cancer (BC) is a major cause of disease and death worldwide. In addition to its contribution to mortality and disability, it is a major economic burden both public and private.ObjectiveTo estimate the average direct medical cost/year of care for the diagnosis and treatment of BC in two coverage scenarios in Mexico: What is ‘ideal’ based on service usage patterns according to international guidelines and what is ‘current’ using the service usage patterns of suppliers in Mexico.Material and MethodsThe pattern and intensity of use of procedures for the care of BC in the Mexican Social Security Institute (IMSS) for 2009 were identified and prices were associated using the guidelines from the System of Social Protection in Health (SPSS) and the IMSS for the current scenario and the ideal scenario, international patterns (Breast Health Global Initiative BHGI after its acronym in English) were used and prices were associated from the SPSS guidelines.ResultsThe annual average direct medical cost per patient in the ‘current’ scenario was 8557 US$, while the cost in the ‘ideal’ scenario was 4554 US$. There are differences in costs between ‘what we do’ and ‘what should be done’, due to differences in the implementation of the interventions for the treatment of the different stages of the disease. A proportional increase in the average cost was also identified as the diagnosis stage advanced (from I to III).ConclusionsGiven that in Mexico there is universal insurance coverage for the treatment of BC, it is necessary to use economic resources more efficiently. It is necessary to continue to examine this topic in more depth and the next step will be to assess the effectiveness of both scenarios in order to provide enough evidence for the decision-making process.

show abstract

Retrospective cost analysis of breast cancer patients treated in a Brazilian outpatient cancer center (OCC).

Cited by 5 publications

References 0 publications

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

Direct Medical Costs for Stage-Specific Breast Cancer: A Retrospective Analysis

The direct medical costs of colorectal cancer in Iran; analyzing the patient′s level data from a cancer specific hospital in Isfahan

Costs of breast cancer care in Mexico: analysis of two insurance coverage scenarios

Contact Info

Product

Resources

About